ReviewCell death discovery2023
Role of ADAM and ADAMTS proteases in pathological tissue remodeling.
Review in Cell death discovery, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
40 citing papers in PubMed, 39 citations in OpenAlex.
- Disulfiram's Anti-Inflammatory and Antibacterial Effects in Fixed-Dose Combination Therapy for Scabies.Pharmaceutics · 2026Article
- Current Advances in the Physiological Roles and Disease-Associated Mechanisms of ADAMTS16.International journal of molecular sciences · 2026Review
- Agarose-Based 3D Invasion Assay for Simultaneous Quantification of Tumor Cell Invasion and Extracellular Matrix Degradation.Methods and protocols · 2026Article
- ADAM and ADAMTS proteases as integrative hubs in heart failure pathogenesis and therapy.iScience · 2026Review
- A cross-ancestry genetic atlas of shared susceptibility between infectious diseases and cancer.Functional & integrative genomics · 2026Article
- When proteases reshape barriers: Basement membrane remodelling in development, wound healing and tumour progression.The FEBS journal · 2026Review
- Cell-autonomous control of CAR signaling and receptor shedding via ADAM17-mediated proteolysis.Cell · 2026Article
- Bioinformatics and experimental validation of druggable targets in non-alcoholic fatty liver disease.Scientific reports · 2026Article
- Functional characterization of podocyte-expressed THSD7A in experimental membranous nephropathy.JCI insight · 2026Article
- Macrophage exosomal ADAM10 mediates alveolar epithelial apoptosis induced by wood smoke PMCell biology and toxicology · 2026Article
- Genome-Wide Identification of Genomic Regions Associated with Body Weight and Morphometric Traits in Awassi Sheep.Animals : an open access journal from MDPI · 2026Article
- Glycocalyx degradation: exploring related mechanisms, pathophysiological significance, and therapeutic prospects.Journal of physiology and biochemistry · 2026Review
- Extracellular matrix proteolysis maintains synapse plasticity during brain development.Nature neuroscience · 2026Article
- The ADAM Family of Proteases: Structure, Substrates, and Roles in Liver Diseases.International journal of molecular sciences · 2026Review
- Elevation-associated shifts in plasma metabolite abundance and lung gene expression in the Xizang plateau frog, Nanorana parkeri.BMC genomics · 2026Article
- miR-22-Galectin-1 as an integral signaling axis in regulating metabolism and immunity in HCC.Biomarker research · 2026Article
- Beyond Structure: The Dynamic Role of the Extracellular Matrix Components in Immune Evasion.Cancer communications (London, England) · 2026Review
- Overview of the Roles of ADAMTS1 in Ovarian Biology.Methods in molecular biology (Clifton, N.J.) · 2026Review
- Curcumin in Fibrosis Treatment: A Review.Drug design, development and therapy · 2026Review
- ADAM12 Stabilizes EIF3B to Promote Glycolysis and Tumor Progression in Hepatocellular Carcinoma.Journal of hepatocellular carcinoma · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pathological tissue remodeling is closely associated with the occurrence and aggravation of various diseases. A Disintegrin And Metalloproteinases (ADAM), as well as A Disintegrin And Metalloproteinase with ThromboSpondin motifs (ADAMTS), belong to zinc-dependent metalloproteinase superfamily, are involved in a range of pathological states, including cancer metastasis, inflammatory disorders, respiratory diseases and cardiovascular diseases. Mounting studies suggest that ADAM and ADAMTS proteases contribute to the development of tissue remodeling in various diseases, mainly through the regulation of cell proliferation, apoptosis, migration and extracellular matrix remodeling. This review focuses on the roles of ADAM and ADAMTS proteinases in diseases with pathological tissue remodeling, with particular emphasis on the molecular mechanisms through which ADAM and ADAMTS proteins mediate tissue remodeling. Some of these reported proteinases have defined protective or contributing roles in indicated diseases, while their underlying regulation is obscure. Future studies are warranted to better understand the catalytic and non-catalytic functions of ADAM and ADAMTS proteins, as well as to evaluate the efficacy of targeting these proteases in pathological tissue remodeling.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.